Studies of malignancies such as leukemia, non-Hodgkin’s lymphoma, bladder cancer, and breast cancer have revealed elevated CD47 levels in tumor cells, with high CD47 expression correlating with poor clinical prognosis [28]. This evidence concerns the gene CD47 and breast carcinoma.